Xilio Therapeutics is a development-stage biotechnology company
advancing next-generation cancer immunotherapies designed to
improve patient outcomes by unleashing the power of the immune
system selectively at the site of the tumor. The company’s
tumor-selective immunotherapies are based on its proprietary
technology, which maximizes the potency of proven immuno-oncology
therapies and restricts their activity to the tumor to minimize
peripheral side effects. The broad applicability of these therapies
across cancer types means that all patients could benefit from
these potentially curative medicines.
Xilio was founded in 2016, and closed a $100.5M Series B
financing from blue chip venture investors in February 2020. Xilio
is headquartered in Waltham, MA.
We are looking for a highly energetic and motivated (Associate)
Director to lead our DMPK efforts. This person will be responsible
for detailed discovery and non-clinical DMPK characterization of
novel biologics based tumor selective immunotherapies. The
successful candidate will have wide-ranging responsibilities within
research and development focused project teams and the opportunity
to work within a highly collaborative, dynamic, and
The position will be based in Waltham, Massachusetts, and
reports to the Vice President, Pharmacology
Provide bioanalytical and assay expertise to enable pre-clinical
pharmacologic assessments of novel biologics-based tumor selective
Collaborate effectively with the research team to develop and
execute pre-clinical assays and validate those for use in
non-clinical and clinical studies, including assays to assess PK,
ADA and neutralizing antibodies
Develop interdisciplinary collaborations and ensure DMPK
analyses, studies and priorities are integrated into overall
project team strategy.
Work with external collaborators and service providers to
support key project goals including quantitative systems
pharmacology modeling to inform non-clinical and clinical
Responsible for the design and interpretation of DMPK assays,
studies and technical report writing necessary for the selection of
clinical candidates and for the filing of regulatory documents.
Candidate should have a Ph.D. or equivalent in a relevant
scientific discipline, pharmacology or pharmaceutical sciences with
8+ years of experience in DMPK roles
Experience with discovery and development of novel biologics
therapies, including reagent generation, and assay development to
support PK studies, and assessment of ADA and neutralizing
Experience with writing of technical reports in support of
Strong understanding of guidance from regulatory agencies on
DMPK assay development and qualification
Excellent communication skill with ability to function within
cross functional teams.
Ability to independently design experiments, analyze
experimental data and present results in both non-clinical and
clinical development team settings.
Goal oriented, organized, capable of prioritizing and working on
multiple projects, and able to execute to timelines that meet
Excellent verbal and written communication skills
Driven by a desire to create the next generation of
immunotherapy-based cancer therapeutics and the vision to offer
cancer patients efficacious and tolerable new therapies that extend
and improve their lives.
Xilio offers the opportunity to work in an innovation driven,
exciting biotechnology company doing ground-breaking work in the
field of immuno-oncology. We offer a competitive compensation
package including a base salary, annual bonus potential, stock
options, 401k, healthcare benefits and paid time-off.
POSITION: Full-Time, Exempt
EEOC Statement: Xilio Therapeutics believes in a diverse
environment, and is committed to equal employment opportunity for
all its employees and qualified applicants. We do not discriminate
in recruitment, hiring, training, promotion or any other employment
practices for reasons of race, color, religion, gender, national
origin, age, sexual orientation, marital or veteran status,
disability, or any other legally protected status. Xilio will make
reasonable accommodations for qualified individuals with known
disabilities, in accordance with applicable law.
Are you Authorized to work lawfully in the United States
Will you now or in the future require Xilio to commence
(“sponsor”) an immigration case in order to employ you (for
example, H-1B or other employment-based immigration case)?